相关实验视频

Updated: May 9, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

扎波丁通过向PKCε介导的糖分解路调节来缓解乳腺癌的进展

Khushbukhat Khan¹, Maryam Anwar¹, Yasmin Badshah¹

¹Department of Biomedicine, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, 44000, Pakistan.

|April 28, 2025

概括

扎波丁是一种天然的黄类化合物,通过向PKCε,降低细胞活力和影响代谢途径,显示出治疗乳腺癌的潜力. 这为乳腺癌治疗提供了一个有希望的新途径.

科学领域:

生物化学生化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

乳腺癌复发率和化学抵抗率的增加需要新的治疗策略.
蛋白质激酶Cepsilon (PKCε) 通过缺氧和代谢重编程与化学抵抗有关.
扎波丁是一种天然的黄类化合物,可能会影响PKCε的表达,从而成为潜在的治疗标.

研究的目的:

为了研究扎波丁对乳腺癌细胞PKCε表达的作用.
分析扎波丁对乳腺癌代谢概况的影响.
探索Zapotin作为一种潜在的治疗药物来治疗乳腺癌.

主要方法:

药分析和分子动力学模拟以评估扎波-PKCε相互作用.
使用MCF-7和MDA-MB-231细胞系进行体外研究,以评估Zapotin的影响.
使用实时PCR,细胞活力测定和气体染色体质谱法.

主要成果:

在 silico 分析表明zapotin具有有利的药理动力学特性,具有低毒性.
扎波丁证明了癌细胞特异性细胞毒性,并降低了乳腺癌细胞活力,殖民地形成和迁移.
扎波丁向PKCε,HIF-1ɑ和VEGF信号通路,并影响了糖溶性代谢.

结论:

经PKCε介导的途径 (HIF-1ɑ,VEGF,糖解) 在乳腺癌的进展中至关重要.
扎波丁具有作为各种乳腺瘤类型的治疗剂的潜力.
这项研究强调了扎波在调节乳腺癌关键途径方面的作用.

关键词:

乳腺癌乳腺癌乳腺癌模拟MDMD的模拟代谢的重新连接蛋白质激酶C epsilon是一种蛋白质激酶.扎波丁·扎波丁 (Zapotin Zapotin) 是一个西班牙人.

更多相关视频

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...